EUTECNIQAtlas

Every page of EUTECNIQ on one mapArrow keys move through results · Enter opens · Esc closes

Supplements A–Z · by effect 42 graded findings

Colds and immune function

What human research has studied for colds, respiratory infections and immune measures, across every ingredient in this guide, strongest evidence first. A grade describes the evidence, not a recommendation.

Education, not medical advice. These statements have not been evaluated by the Food and Drug Administration. This information is not intended to diagnose, treat, cure or prevent any disease, or to replace any medication or medical advice. Ask a doctor or pharmacist before use, especially with medicines, in pregnancy or for a child.

Summary

How strong the evidence is

Show

Where colds and immune function sits on the supplement body map; colored by its strongest grade here.

Findings

Findings by ingredient

Colds and immune function: findings by ingredient and grade
IngredientGradeWhat was studied and found
Vitamin AAMeasles in children. A 2022 Cochrane review found vitamin A supplementation reduced new cases of measles in children (RR 0.45, 95% CI 0.30 to 0.69; 2 studies, 1,982 children) but showed no evidence of a difference in deaths from measles (RR 0.88, 0.69 to 1.11). sources
Vitamin CACommon cold duration. In the 2013 Cochrane review, regular use modestly shortened colds by 8% in adults and 14% in children; taking vitamin C after symptoms began had no consistent effect on duration or severity. sources
AndrographisBSymptoms of acute respiratory tract infections (colds, sore throat, cough). A 2017 meta-analysis of 33 RCTs (7,175 patients) found improved cough and sore throat versus placebo and shorter symptom duration versus usual care; overall trial quality was poor. sources
ElderberryBUpper respiratory symptoms (colds, flu). A 2019 meta-analysis of randomized trials with 180 participants in total reported reduced upper respiratory symptoms; NCCIH describes the research as preliminary and few in number. sources
Lacticaseibacillus rhamnosus GG (LGG)BRespiratory infections. A 2025 meta-analysis of 69 LGG trials found lower respiratory infection risk (RR 0.87; 18 trials) but limited effects on respiratory symptoms; certainty was mostly low beyond diarrhea outcomes and adult evidence was limited. sources
LactoferrinBLate-onset sepsis and necrotizing enterocolitis in preterm infants. A 2020 Cochrane review (12 RCTs, 5,425 preterm infants) found lactoferrin added to enteral feeds reduced late-onset sepsis (RR 0.82; low certainty) but not NEC stage II–III or all-cause mortality. sources
LactoferrinBRespiratory tract infections and inflammation markers. A 2022 meta-analysis (25 studies) found fewer respiratory infections in infants and children (OR 0.78) but not in adults (OR 1.00); in adults lactoferrin lowered IL-6 but not C-reactive protein. sources
Pelargonium sidoidesBAcute bronchitis in adults and children. A Cochrane review found three trials in adults (746 patients) and three in children (819) showing benefit for most outcomes with the liquid preparation but not tablets; evidence quality was low. sources
Pelargonium sidoidesBRecovery and paracetamol use in children with bronchitis or tonsillopharyngitis. An individual-data meta-analysis of six placebo-controlled trials (523 children aged 6–10) found less paracetamol use and fewer children off school at treatment end; two authors were employees of Dr. Willmar Schwabe GmbH. sources
ZincBDuration of the common cold. A 2024 Cochrane review (34 trials, 8,526 participants) found zinc may shorten symptoms by about 2 days, with little to no difference in catching colds; certainty was low to very low. sources
American ginsengCCommon colds in healthy adults (taken preventively). A 2011 review of five trials (747 participants, all of North American ginseng) found insufficient evidence on cold incidence or severity; two pooled trials showed colds or respiratory infections 6.2 days shorter. sources
AndrographisCMild-to-moderate COVID-19. A 2025 meta-analysis of six RCTs (660 adults) found no significant improvement in fever or cough resolution, CRP or IL-6 versus antivirals or supportive care. sources
AstragalusCImmune response and inflammatory markers. A 2023 review of 19 studies (1,094 participants) reported enhanced immune responses and lower proinflammatory cytokines; the studies were small and differed widely in methods. sources
Bifidobacterium animalis subsp. lactis BB-12CRespiratory infections in healthy infants. In an RCT of 109 one-month-old infants given BB-12 tablets to 8 months, fewer respiratory infections were reported (65% vs 94%); gastrointestinal symptoms, otitis media and antibiotic use did not differ. sources
BromelainCSinusitis. NCCIH: a small number of studies have been done; there is not enough high-quality research to say whether oral bromelain should be recommended for sinusitis. sources
CordycepsCImmune measures in healthy men (C. militaris). RCT in 79 healthy Korean men: 1.5 g/day ethanol-treated C. militaris for 4 weeks increased NK cell activity and lymphocyte proliferation more than placebo. sources
EchinaceaCCatching a cold (prevention trials). Cochrane (2014): none of 12 prevention comparisons was statistically significant; post hoc pooling suggested a 10% to 20% relative risk reduction of questionable clinical relevance. sources
EchinaceaCDuration of colds (treatment trials). Of seven treatment trials reporting cold duration, only one showed a significant effect; Cochrane authors said benefits were not shown but a weak benefit from some products is possible (24 trials, 4,631 participants). sources
EchinaceaCRespiratory infections in children. One recent study suggested fewer infections, but NCCIH states overall evidence is insufficient to support a clear connection. sources
ElderberryCCOVID-19. NCCIH states there is insufficient evidence that elderberry helps COVID-19 symptoms. sources
FucoidanCInflammation and immune measures. 2026 systematic review of 5 clinical studies: some trials reported lower inflammatory cytokines or NK-cell changes, but findings were not consistently replicated; evidence is limited and heterogeneous. sources
GarlicCCommon cold. Cochrane (2014) found one trial: 146 people, 12 weeks; 24 colds with garlic versus 65 with placebo, self-reported; authors call the evidence insufficient. sources
Lacticaseibacillus paracasei strain Shirota (LcS)CUpper respiratory infections in middle-aged office workers. In an RCT of 96 male office workers, 12 weeks of LcS fermented milk was associated with fewer upper respiratory tract infections than control milk (22.4% vs 53.2%). sources
Licorice rootCCOVID-19. NCCIH states there is no good evidence for licorice in COVID-19. sources
MaitakeCImmune measures in breast cancer survivors. Phase I/II trial in 34 postmenopausal women free of disease: a liquid extract (0.1–5 mg/kg twice daily, 3 weeks) both raised and lowered different immune measures, with non-monotonic dose responses. sources
MaitakeCImmune cell function in myelodysplastic syndromes. Phase II study (21 enrolled, 18 evaluable): 3 mg/kg twice daily for 12 weeks increased neutrophil and monocyte function in laboratory tests; there was no placebo group. sources
Pelargonium sidoidesCAcute sinusitis and the common cold in adults. Single trials: one in 103 adults with sinusitis showed benefit at day 21; one in the common cold showed benefit at 10 days but not 5. Cochrane rated this evidence very low quality. sources
Sea buckthornCCommon colds and digestive infections in healthy adults. In an RCT of 254 healthy adults, sea buckthorn berries did not change the number or duration of colds or digestive tract infections; serum CRP decreased slightly versus placebo. sources
ShiitakeCImmune measures in healthy young adults. 52 adults aged 21–41 ate 5 or 10 g of dried shiitake daily for 4 weeks: gamma-delta T and NK-T cell proliferation and salivary IgA increased, and CRP fell. There was no placebo group. sources
SpermidineCVaccine responses in adults over 65. A randomized pilot trial in 40 adults (6 mg/day for 13 weeks after a third SARS-CoV-2 vaccine dose) reported stronger antibody and memory B-cell responses, specifically in vaccine non-responders. sources
Streptococcus salivarius K12CSore throat (pharyngotonsillitis) in children and adults. A 2019 systematic review found 4 RCTs (1,846 participants), all poor quality: two child trials versus no treatment reported benefit (pharyngitis, adenoiditis), a 1,314-child placebo trial found none, and an adult trial alongside penicillin showed none. sources
Streptococcus salivarius K12CUpper respiratory infections in physically active young adults. In a double-blind RCT of 112 adults aged 19–25, symptom severity did not differ from placebo over four months; participants with over 90% adherence reported more symptom-free days. sources
Sutherlandia (cancer bush)CHIV viral load and CD4 count in adults with HIV. In a 24-week randomized, placebo-controlled trial (107 analyzed), 1,200 mg twice daily did not change viral load or CD4 count, and days of infection-related events were higher with sutherlandia. sources
Sweet wormwoodCMalaria (whole-plant tea or powder instead of medicines). WHO does not support use of Artemisia plant material in any form for malaria: content varies, is often insufficient to kill all parasites, and widespread use could hasten artemisinin resistance. sources
Sweet wormwoodCMalaria parasite clearance in randomized trials of A. annua tea. A 2026 systematic review found rapid early parasite clearance, but day-28 parasitological outcomes with tea alone fell consistently below the 95.5-98.6% benchmark for artemisinin-based combination therapy. sources
ThymeCAcute bronchitis with productive cough (thyme–ivy combination). A double-blind RCT in 361 adults found a thyme–ivy syrup (5.4 ml three times daily, 11 days) cut daytime coughing fits by 68.7% versus 47.6% with placebo; thyme was not tested alone. sources
ZincCPneumonia in young children. A 2016 Cochrane review (6 trials, 5,193 children) found 10–20 mg/day lowered pneumonia incidence; a 2020 meta-analysis found adjunctive zinc did not change mortality or recovery time. sources
ZincCHIV outcomes. Single trials reported fewer immunological failures or infections, but a Cochrane review (6 trials, 826 adults) found little or no effect on CD4 counts or viral load. sources
Lacticaseibacillus paracasei strain Shirota (LcS)XRespiratory symptoms in nursing-home residents aged 65 or older. In a double-blind RCT of 737 residents in 53 nursing homes, 176 days of LcS fermented milk had no significant effect on respiratory symptoms or on antibody response to influenza vaccination. sources
Lactiplantibacillus plantarum 299vXOutcomes of adults in intensive care. In a multicenter RCT of 218 adult ICU patients, 60 days of 299v did not change days alive and out of hospital (median 49.5 vs 49.0) or nosocomial infection (7.3% vs 4.6%). sources
Streptococcus salivarius K12XAcute otitis media in children attending day care. In a double-blind RCT of 827 children aged 1–6 years, 6 months of K12 (1 x 10^9 CFU/day) did not reduce otitis media needing antimicrobial therapy (8.2% vs 5.8% with placebo). sources
Vitamin CXCommon cold incidence. A 2013 Cochrane review of placebo-controlled trials using at least 200 mg/day found regular use did not reduce colds in the general community (RR 0.97; 10,708 participants); in 5 trials of 598 marathon runners, skiers and soldiers, it roughly halved cold risk (RR 0.48). sources
A
Consistent results from several randomized trials or a systematic review of them
B
Some positive randomized trials, but small, short, few or inconsistent
C
Limited human evidence: single small trials, observational data or mixed results
D
Laboratory or animal evidence only; not shown in people
X
Well-designed human trials found no meaningful effect

All effect categories · All entries A–Z · Interactions

Health information notice

These statements have not been evaluated by the Food and Drug Administration. Nothing on this site is intended to diagnose, treat, cure or prevent any disease. The information is for general education only. It is not medical advice and does not replace advice, diagnosis or treatment from a qualified health professional, or any medication a clinician has prescribed.

Do not start, stop or change any medicine, supplement or herbal product because of something you read here. Talk to your doctor or pharmacist first, especially if you are pregnant or breastfeeding, have a medical condition, take any medicines, are preparing for surgery, or are caring for a child. Research findings, traditional uses and safety data are reported as their sources state them; they are not recommendations or claims about any product. If you think you may have a medical emergency, call your doctor or 911 at once.

EUTECNIQ Sciences sells no supplements or health products today and receives nothing from any product or ingredient mentioned on this site; any commercial interest it later has in an ingredient will be stated on that ingredient’s page.

Ready to check what you take?

Free tools built on published reference values, each with its sources and its limits. Your lists stay in your browser.